Last reviewed · How we verify
NCT06622304: MRDLT
Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels
trial in Hypertension in 250,736 participants. Completed in 11 September 2024.
1 August 2024
Quick facts
| Lead sponsor | Guangzhou Institute of Respiratory Disease |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 250,736 |
| Start date | 1 April 2024 |
| Primary completion | 1 August 2024 |
| Estimated completion | 11 September 2024 |
| Sites | 1 location across China |
Conditions studied
- Hypertension — all drugs for Hypertension →
- Dyslipidemias — all drugs for Dyslipidemias →
- Inflammatory Response — all drugs for Inflammatory Response →
- Chronic Inflammation — all drugs for Chronic Inflammation →
Sponsor
Guangzhou Institute of Respiratory Disease
Who can join
18 and older, any sex, with Hypertension or Dyslipidemias. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigates the causal relationships between antihypertensive and lipid-lowering drugs and inflammatory cytokines using a drug-targeted Mendelian randomization approach. By leveraging genome-wide association studies (GWAS) and expression quantitative trait loci (eQTL) data, the study evaluates the effects of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), HMG-CoA reductase inhibitors, PCSK9 inhibitors, and NPC1L1 inhibitors on key inflammatory cytokines such as IL-1β, TNF-α, CRP, and MCP-1. The findings aim to provide insights into the prevention and control of excessive inflammatory responses, particularly in patients with hypertension and dyslipidemia, by assessing the causal effects of these therapies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mendelian randomization-based observational cohort study on drug targets: Impact of antihypertensive and lipid-lowering therapies on inflammatory cytokines.
Xin J, Xu Z, Zhang F, Sun Y, et al · · 2025 · PMID 40068040 · DOI 10.1097/md.0000000000041771
Verify or expand the search:
- PubMed search for NCT06622304
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other Guangzhou Institute of Respiratory Disease trials
Trials by the same sponsor.
- NCT07092137 — Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer · Phase 2 · not yet recruiting
- NCT06909383 — Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Can · Phase 2 · not yet recruiting
- NCT07005999 — Interventional Ablation for Early-stage Lung Cancer · active not recruiting
- NCT06739928 — Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC · Phase 2 · recruiting
- NCT06715956 — Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06622304 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Institute of Respiratory Disease
- Last refreshed: 3 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06622304.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing